We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Nexstim
Hitting the right spotScancell
COVID 2nd generation vaccine opportunity is all upsideScancell
Reasons to be cheerfulMaxCyte
CRISPR-Cas9 gene editing pioneer secures licenceBerGenBio
NOK500m raised to drive bemcentinib progressMaxCyte
£25.1m ($31.0m) successully raisedNexstim
€2.3m rights issue to progress both NBS and NBTHutchison China MediTech
AACR 2020: first surufatinib/PD-1 combo dataBerGenBio
Bemcentinib fast-tracked into COVID-19 trialMaxCyte
FY19 results crown a breakthrough year